MET exon 14 skipping mutation
Showing 1 - 25 of >10,000
Metastatic NSCLC MET Exon 14 Skipping Mutation and Brain
Completed
- Metastatic Non-Small Cell Lung Cancer
-
East Hanover, New Jersey18 Novartis Investigative Sites in the US
Dec 29, 2022
Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer Trial in San Francisco (Capmatinib, Trametinib)
Recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer
-
San Francisco, CaliforniaUniversity of California San Francisco
Aug 15, 2022
Non-Small Cell Lung Carcinoma Trial (Capmatinib 150 mg, Capmatinib 200 mg)
Recruiting
- Non-Small Cell Lung Carcinoma
- Capmatinib 150 mg
- Capmatinib 200 mg
-
Guwahati, Assam, India
- +7 more
Dec 19, 2022
NSCLC, RET Driver Mutation, BRAF V600 Mutation Trial in Guanzhou (Toripalimab, Nab paclitaxel, Pemetrexed)
Recruiting
- Non-Small Cell Lung Cancer
- +5 more
- Toripalimab
- +3 more
-
Guanzhou, Guangdong, ChinaGuangdong Lung Cancer Institute, Guangdong Provincial People's H
Apr 4, 2023
NSCLC (NSCLC) Trial in China (Capmatinib)
Recruiting
- Non-Small Cell Lung Cancer (NSCLC)
-
Xiamen, Fujian, China
- +18 more
Jan 27, 2023
NSCLC Trial in Guangzhou (PLB1001)
Active, not recruiting
- Non-small Cell Lung Cancer
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Aug 15, 2023
NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation Trial in Guangzhou (Dabrafenib + Trametinib, Capmatinib)
Not yet recruiting
- NSCLC
- +2 more
- Dabrafenib + Trametinib
- Capmatinib
-
Guangzhou, Guangdong, ChinaCancer Center of Sun-Yat Sen University
Sep 19, 2023
Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping
Recruiting
- Non-small Cell Lung Cancer
-
Changsha, Hunan, ChinaYongchang Zhang
Mar 1, 2022
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (procedure, biological, drug)
Not yet recruiting
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Biospecimen Collection
- +5 more
- (no location specified)
Sep 7, 2023
Special Drug Use-results Surveillance of Tabrecta Tablets
Recruiting
- Non-small Cell Lung Cancer
- Tabrecta tablets
-
Nagoya, Aichi, Japan
- +44 more
Aug 1, 2022
Malignant Non-small Cell Tumor of Lung Stage IV Trial in Boston (Capmatinib (INC280))
Completed
- Malignant Non-small Cell Neoplasm of Lung Stage IV
- Capmatinib (INC280)
-
Boston, MassachusettsMassachusetts General Hospital
Mar 11, 2022
Gastric Cancer, Gastroesophageal-junction Cancer Trial in Gyeonggi-do (Tepotinib plus paclitaxel)
Recruiting
- Gastric Cancer
- Gastroesophageal-junction Cancer
- Tepotinib plus paclitaxel
-
Gyeonggi-do, Korea, Republic ofHallym University Medical Center
Jun 29, 2022
Gastrointestinal Stromal Tumors Trial in Houston (Regorafenib)
Not yet recruiting
- Gastrointestinal Stromal Tumors
-
Houston, TexasM D Anderson Cancer Center
Oct 12, 2023
Advanced Cancer, Non Small Cell Lung Cancer Trial (Tepotinib, Pembrolizumab)
Not yet recruiting
- Advanced Cancer
- Non Small Cell Lung Cancer
- (no location specified)
Mar 28, 2023
NSCLC, Solid Tumor Trial in Boston (Merestinib)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Solid Tumor
-
Boston, Massachusetts
- +1 more
Jan 26, 2022
NSCLC Trial in Worldwide (Capmatinib, Amivantamab)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
-
Orange, California
- +40 more
Aug 3, 2022
Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients
Recruiting
- Lung Neoplasms
- +3 more
- Observation
-
Shanghai, ChinaShanghai Chest Hospital
Mar 14, 2022
NSCLC Metastatic Trial in Shanghai (Savolitinib)
Recruiting
- Non-small Cell Lung Cancer Metastatic
-
Shanghai, Shanghai, ChinaShanghai Chest Hospital
Aug 30, 2021
Muscular Dystrophy, Duchenne, DMD Trial (viltolarsen)
Approved for marketing
- Muscular Dystrophy, Duchenne
- DMD
- (no location specified)
Aug 14, 2020
Met Non Small Cell Cancer Registry (MOMENT)
Recruiting
- Cancer
-
Fort Lauderdale, Florida
- +53 more
Nov 3, 2022